Intellia Therapeutics, Inc.

NTLASEC EDGAR

In Vitro & In Vivo Diagnostic Substances(DE)CIK: 1652130

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$36.3M	$52.1M	$33.1M	$58.0M	$43.1M
Cost of Goods and Services Sold	—	—	—	—	$0.00
Research and Development Expense	$435.1M	$420.0M	$229.8M	$150.4M	$108.4M
Operating Income (Loss)	-$515.3M	-$458.2M	-$267.9M	-$136.6M	-$106.4M
Other Nonoperating Income (Expense)	$34.1M	-$16.0M	-$42.0K	$2.4M	$6.8M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	—	—
Income Tax Expense (Benefit)	$0.00	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.2B	$1.3B	$1.5B	$1.3B	$676.3M
Assets, Current	$639.9M	$998.3M	$1.2B	$769.3M	$616.5M
Cash and Cash Equivalents, at Carrying Value	$226.7M	$523.5M	$123.4M	$160.0M	$57.2M
Accounts Receivable, after Allowance for Credit Loss, Current	$36.5M	$3.8M	$2.0M	$2.1M	$4.6M
Liabilities	$319.1M	$250.8M	$284.5M	—	—
Liabilities, Current	$110.9M	$115.2M	$126.6M	$125.8M	$64.3M
Accounts Payable, Current	$14.6M	$7.5M	$5.2M	$9.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$394.1M	-$333.3M	-$225.0M	-$49.9M	-$103.2M
Net Cash Provided by (Used in) Investing Activities	-$31.3M	$160.3M	-$550.8M	-$214.5M	$25.2M
Net Cash Provided by (Used in) Financing Activities	$130.3M	$583.0M	$736.7M	$371.8M	$76.4M
Payments to Acquire Property, Plant, and Equipment	$14.0M	$13.6M	$12.8M	$3.6M	$6.8M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)